UNSPSC 85603108: Revision of autologous tissue substitute in large intestine, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to revision of autologous tissue substitute in large intestine, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0DWE47Z

UNSPSC 85603108 Revision of autologous tissue substitute in large intestine, percutaneous endoscopic approach, Commodity tier, shows minimal alignment with recent state and local procurement activity. The code's nominal scope describes a specific surgical procedure—revision of autologous tissue grafts in the colon via endoscopic technique—yet the six most recent opportunities posted under this classification involve occupational medical surveillance, independent medical evaluations for disability benefit determination, pharmacy benefit management, surgical carve-out networks, temporary health professional staffing, and emergency medical services for youth in custody. None of these solicitations involve autologous tissue procedures, revision surgeries, or endoscopic interventions. The issuing bodies span a state department (Washington State Department of Transportation), county health systems and boards (Santa Clara Health System, Harris County Juvenile Probation Department, Collier County), and municipal retirement offices (City of Phoenix), indicating diverse buying entities. Geographic spread includes Arizona, California, Florida, Texas, and Washington State.

The mismatch between the code's clinical definition and the actual procurements posted under it suggests either systematic misclassification at the source, misapplication during opportunity posting, or that the code captures administrative or billing functions tangentially related to surgical services rather than the procedures themselves. Without recent solicitations specifically seeking autologous tissue substitutes, surgical revision services, or endoscopic procedures, the code does not offer a reliable signal for business development targeting state and local surgical procurement. Firms pursuing state and local opportunities in specialty surgical care or tissue engineering should verify procurement classification directly with issuing bodies rather than rely on this code's recent activity.